According to Peter Mansell of
Pharma Times, a new study by Frost & Sullivan, Strategic Analysis of Opportunities in the CRO Market – Phase 0, notes the increasing acceptance of microdosing and suggests it may be the antidote to industry’s much-discussed problems with drug productivity. Consolidation among CROs has raised concerns about quality of service and attention to detail in the sector, Frost & Sullivan points out. Mansell points out that companies need to ensure these elements are in place if they are to maintain their bargaining power with the pharmaceutical industry. For more information on the study or Peter Mansell's thoughts, check out the original article,
here.
|
Share this article with your social network, just click below to share now!
|
|
|
photo credit: @KimTweetsDC For over 20 years we have been working hard on delivering you with first-hand insights into one of the mo...
Last month we blogged about five women to watch in Boston biotech and got an incredible response. In a country where less than five percent...
No comments :
Post a Comment